Portfolio companies.
34,000+ PE-backed.

Active investments and exits across European private equity portfolios.
Filter by sector, geography, status. Find the right deal comp in seconds.

Active deals

241

currently held

Exits tracked

163

hand-checked

Sectors covered

across the portfolio

Countries covered

from every market

Latest activityLast event 2026-10-07

BP Technology VenturesadminDirector Departure · Resignation of MORELAND, Jennifer Lynne (director) · director resigned · governance change5 days ago

BP Technology Ventures5 days ago

Director Departure · Resignation of MORELAND, Jennifer Lynne (director) · director resigned · governance change

admin

B.P. Marsh & PartnerscapitalCapital Event · capital-return-purchase-own-shares-treasury-capital-date · Capital structure change5 days ago

B.P. Marsh & Partners5 days ago

Capital Event · capital-return-purchase-own-shares-treasury-capital-date · Capital structure change

capital

Arkea CapitaladminBoard change · Management board member change:: TRIDEAU Thomas, Jérôme · Change in the management board6 days ago

Arkea Capital6 days ago

Board change · Management board member change:: TRIDEAU Thomas, Jérôme · Change in the management board

admin

Caledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change6 days ago

Caledonia Investments6 days ago

Capital Event · capital-cancellation-shares · Capital structure change

capital

Cervinvest CapitaladminCEO change · Appointment of CEO De Jongh, Guillaume · New CEO appointed1 week ago

Cervinvest Capital1 week ago

CEO change · Appointment of CEO De Jongh, Guillaume · New CEO appointed

admin

Cervinvest CapitaladminChairman change · Appointment of Chairman Radix, Maxence. Departure of CEO Rouland, Antoine · New Chairman appointed. CEO departure · leadership transition underway1 week ago

Cervinvest Capital1 week ago

Chairman change · Appointment of Chairman Radix, Maxence. Departure of CEO Rouland, Antoine · New Chairman appointed. CEO departure · leadership transition underway

admin

Company	Sector	Geo	Investor	Entry	Hold	Status	Buyer	MOIC
leon-nanodrugs GmbH BayBG Venture Capital	Pharma	Germany	BayBG Bayerische Beteiligungsgesellschaft	2020	6yr	Active	–	–
Linneo Health Torreal	Pharma	Spain	Torreal	2018	8yr	Active	–	–
MAYOLY SPINDLER CAPZA Flex Equity Mid-Market I	Pharma	France	Capza	2022	4yr	Active	–	–
Medical Plants Realza Capital Fund II	Pharma	Spain	Realza Capital	2021	5yr	Active	–	–
Meribel Pharma Ardian Buyout Fund VII	Pharma	France	Ardian	2020	6yr	Active	–	–
Millicent Pharma Limited Carlyle Global Infrastructure Opportunity Fund	Pharma	United Kingdom	The Carlyle Group	–	–	Active	–	–
MiP Pharma capiton VI	Pharma	Germany	capiton	2020	6yr	Active	–	–
MITEM Pharma TechLife Capital I	Pharma	France	TechLife Capital	2020	6yr	Active	–	–
MPA Pharma Hannover Finanz Evergreen Fund	Pharma	Germany	Hannover Finanz	1998	28yr	Active	–	–
NEC MED PHARMA GmbH NORD Holding Mid Cap	Pharma	Germany	NORD Holding	2016	10yr	Active	–	–
Noucor MCH Iberian Capital Fund V	Pharma	Spain	MCH Private Equity Investments	2022	4yr	Active	–	–
Novaliq dievini Hopp BioTech holding (Evergreen Balance Sheet)	Pharma	Germany	dievini Hopp BioTech holding	2007	19yr	Active	–	–
NTC Wisequity V	Pharma	Italy	Wise Equity SGR	2022	4yr	Active	–	–
OcuMension General Atlantic Portfolio	Pharma	USA	General Atlantic	–	–	Active	–	–
Oxford Drug Design Angel CoFund	Pharma	UK	ACF Investors	2019	7yr	Active	–	–
PerioTrap Pharmaceuticals GmbH Fraunhofer Venture (spin-off equity)	Pharma	Germany	Fraunhofer Venture	2018	8yr	Active	–	–
Pharmacom Scipio Swanlaab SF	Pharma	Austria	Swanlaab Venture Factory	2025	1yr	Active	–	–
Pharmatis Fonds Franco-Africain II (FFA2)	Pharma	France	Africinvest Europe	2024	2yr	Active	–	–
Pharmscript Summit Partners Portfolio	Pharma	USA	Summit Partners	–	–	Active	–	–
Piramal Pharma Limited Carlyle U.S. Private Equity Fund	Pharma	India	The Carlyle Group	–	–	Active	–	–
POC Pharma Alven V	Pharma	France	Alven	2024	2yr	Active	–	–
PrioThera Earlybird Health	Pharma	Ireland	Earlybird Venture Capital	2020	6yr	Active	–	–
ProJect Pharmaceutics AFINUM IX Buyout (2021)	Pharma	Germany	AFINUM Management GmbH	2025	1yr	Active	–	–
Republic M Queen's Park Equity Partners I	Pharma	UK	Queen's Park Equity	2022	4yr	Active	–	–
Revi Pharma Italian Fine Food	Pharma	Italy	AVM SGR	2026	0yr	Active	–	–
Rioja Nature Pharma Tresmares Private Equity Fund II	Pharma	Spain	Tresmares Capital	2023	3yr	Active	–	–
Royalty Pharma General Atlantic	Pharma	United States	General Atlantic	–	–	Active	–	–
Seda BGF	Pharma	UK	BGF	2025	1yr	Active	–	–
Septodont CIC Debt Fund 4	Pharma	France	CIC Private Debt	2023	3yr	Active	–	–
SeQuent Scientific Limited Carlyle Sub-Saharan Africa Fund	Pharma	India	The Carlyle Group	–	–	Active	–	–
SERB Charterhouse Capital Partners X	Pharma	–	Charterhouse Capital Partners	2017	9yr	Active	–	–
SERB Pharmaceuticals Mérieux Participations 3	Pharma	Europe	Merieux Equity Partners	2021	5yr	Active	–	–
SFAN Laboratoire Vivalto Partners Fund I	Pharma	France	Vivalto Partners	2025	1yr	Active	–	–
Shorla Pharma Enterprise Ireland	Pharma	Ireland	Enterprise Ireland	–	–	Active	–	–
Sintetica Ardian Buyout Fund VII	Pharma	Switzerland	Ardian	2019	7yr	Active	–	–
Skyepharma Jadel Evergreen	Pharma	France	Jadel	2021	5yr	Active	–	–
Small Pharma Angel CoFund	Pharma	UK	ACF Investors	2017	9yr	Active	–	–
Start Center For Cancer Research Warburg Pincus Global Growth 14, L.P.	Pharma	United States	Warburg Pincus	–	–	Active	–	–
Swixx Stags Participations	Pharma	France	Stags Participations	2020	6yr	Active	–	–
ten23 health 3i Group plc (Evergreen balance sheet)	Pharma	Switzerland	3i	2021	5yr	Active	–	–
THX Pharma Odyssee Venture Funds	Pharma	France	Odyssée Venture	2025	1yr	Active	–	–
Torbay Pharmaceuticals NorthEdge Fund III	Pharma	UK	NorthEdge Capital	2023	3yr	Active	–	–
tranScrip Palatine Impact Fund II	Pharma	UK	Palatine Private Equity	2021	5yr	Active	–	–
Trifarma Principia III - Health	Pharma	Italy	Principia SGR	2017	9yr	Active	–	–
Unolab Manufacturing ProA Capital Iberian Buyout Fund II	Pharma	Spain	ProA Capital	2016	10yr	Active	–	–
Verretubex FPCI Capitem 1	Pharma	France	Capitem Partenaires	2014	12yr	Active	–	–
Viyash Life Sciences Private Limited Carlyle Asia fund	Pharma	India	The Carlyle Group	–	–	Active	–	–
Zentiva CM-CIC Debt Fund 3	Pharma	Czech Republic	CIC Private Debt	2020	6yr	Active	–	–
Zevra Therapeutics TVM Life Science Ventures	Pharma	United States	TVM Capital Life Science	2023	3yr	Active	–	–
Nuclidium5 periods Wellington Partners Life Sciences	Pharma	France	Wellington Partners	2025	1yr	Active	–	–

Portfolio companies.34,000+ PE-backed.

Portfolio companies.
34,000+ PE-backed.